Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Cancer Res. 2014 Oct 15;74(23):6947–6957. doi: 10.1158/0008-5472.CAN-14-1592

Figure 4. Evidence for a dominant set of NFATc1 target genes.

Figure 4

(A) Expression of eight putative target mRNA species significantly associated with NFATc1 expression in MC38Met cells following FK506 treatment (relative to DMSO control, n=4, significance is determined by 1-sample t-test against equivalence or ratio=1 as shown by verticle line). (B) Expression of eight mRNA species significantly associated with NFATc1 expression in HCT116 cells following treatment with NFATc1 specific RNAi (relative to siSCR, n=4, significance is determined by 1-sample t-test against equivalence or ratio=1 as shown by verticle line).(C) Quantification of NFATc1 pull-down on putative target gene specific promoter binding elements relative to IgG control (ASPN mRNA species undetectable, not shown). ns=p>0.05, *p<0.05,**p<0.005,***p<0.0005, ****p<0.00005.